Walgreens and CVS Under Investigation by FDA for Selling Unapproved--and Potentially Unsafe--Eye Drop Products
24 Oct 2023
SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP has launched an investigation into Walgreens and CVS after the U.S. Food & Drug Administration issued warning letters to manufacturers of eye drop products. Walgreens and CVS marketed certain non-FDA approved eye drop products as treatment for medical conditions.
These products include:
Walgreens Allergy Eye Drops
Walgreens Stye Eye Drops
Walgreens Pink Eye Drops
CVS Health Brand Pink Eye Relief Eye Drops
Walgreens and CVS marketed certain eye drop products as treatments for medical conditions such as conjunctivitis, cataracts, and glaucoma. However, according to the FDA, these products are "drugs" under the Food, Drug, & Cosmetic Act, which. defines drugs as "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals."
On September 12, 2023, the FDA announced that it was "particularly concerned that these illegally marketed, unapproved ophthalmic drug products pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body's natural defenses". In its warning letter to Walgreens, the FDA noted that Walgreen's ophthalmic drug products utilize silver sulfate as a preservative. This is a concern because long term use of medicinal compounds containing silver may cause argyria (a blueish-gray discoloration of the skin and eyes that is irreversible). It may also cause adverse effects on night vision.
In light of these concerns, the Schubert Firm is investigating whether CVS and Walgreens have violated state and federal laws by selling unapproved—and potentially unsafe—eye drop products. If you purchased one of these products, you may be entitled to a refund and an injunction requiring CVS and Walgreens to stop selling them.
contact us
today or visit our website at
https://www.classactionlawyers.com/eyedrops
.
About Schubert Jonckheer & Kolbe LLP
Schubert Jonckheer & Kolbe represents shareholders, employees, and consumers in class actions against corporate defendants, as well as shareholders in derivative actions against their officers and directors. The firm is based in San Francisco, and with the help of co-counsel, litigates cases nationwide.
Contact
Amber L. Schubert
Schubert Jonckheer & Kolbe LLP
[email protected]
Tel: (415) 788-4220
SOURCE Schubert Jonckheer & Kolbe LLP
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.